Avoro Capital Advisors LLC Cuts Stock Position in MoonLake Immunotherapeutics $MLTX

Core Viewpoint - Avoro Capital Advisors LLC significantly reduced its holdings in MoonLake Immunotherapeutics by 51.8% in the third quarter, indicating a shift in investment strategy towards the company [2]. Institutional Holdings - Avoro Capital Advisors LLC now holds 2,000,000 shares of MoonLake Immunotherapeutics, down from 4,150,000 shares, representing approximately 0.2% of its portfolio and making it the 27th largest holding [2]. - Other institutional investors have also adjusted their positions, with Elevation Point Wealth Partners LLC purchasing a new position valued at approximately $74,000 and Covestor Ltd acquiring shares worth about $46,000 [3]. - BNP Paribas Financial Markets increased its holdings by 18.9%, now owning 7,296 shares worth $52,000 after buying an additional 1,158 shares [3]. - Fox Run Management L.L.C. and WINTON GROUP Ltd also acquired new stakes valued at $82,000 and $593,000 respectively [3]. - Institutional investors and hedge funds collectively own 93.85% of MoonLake Immunotherapeutics [3]. Analyst Ratings - Oppenheimer raised its price target for MoonLake Immunotherapeutics from $30.00 to $35.00, maintaining an "outperform" rating [4]. - Royal Bank Of Canada increased its price objective from $12.00 to $13.00, giving a "sector perform" rating [4]. - BTIG Research raised its target price from $24.00 to $30.00 with a "buy" rating [4]. - Zacks Research upgraded the stock from "strong sell" to "hold" [4]. - The Goldman Sachs Group downgraded the stock from "neutral" to "sell," increasing its price target from $8.00 to $10.00 [4]. - The consensus rating for MoonLake Immunotherapeutics is "Hold" with an average price target of $27.85 [4]. Stock Performance - MoonLake Immunotherapeutics shares opened at $17.13, with a market capitalization of $1.23 billion [5]. - The stock has a 50-day moving average of $16.52 and a 200-day moving average of $20.73 [5]. - The company has a price-to-earnings ratio of -4.87, a current ratio of 9.27, and a debt-to-equity ratio of 0.24 [5]. - The stock has experienced a 12-month low of $5.95 and a high of $62.75 [5]. Earnings Report - The company reported earnings per share of ($0.92) for the last quarter, matching analysts' consensus estimates [6]. - This compares to ($0.72) EPS in the same quarter the previous year [6]. - Analysts expect MoonLake Immunotherapeutics to post an EPS of -1.79 for the current year [6]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on developing therapies, including Sonelokimab for treating inflammatory diseases [7]. - The company was incorporated in 2020 and is headquartered in Zug, Switzerland [7].